UNSPSC 51273103: Minaxolone

This classification denotes an anesthetic agent with the molecular formula C25H43NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 737SKC73L0, chemically known as pregnan-20-one, 11-(dimethylamino)-2-ethoxy-3-hydroxy-, (2beta,3alpha,5alpha,11alpha)- but generally known as minaxolone, which bears US NIH Compound Identifier 71960. European Medicines Agency schedules Minaxolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08975MIG.

UNSPSC 51273103 Minaxolone, a Commodity code, covers pharmaceutical products that state and local governments procure for emergency response, public health, and community health programs. Recent solicitations show state and local agencies buying naloxone (opioid reversal medication), safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products through competitive bidding and cooperative purchasing arrangements. The work spans direct procurement of emergency medical supplies for county health departments, participation in multistate cooperative pharmaceutical contracts, and exploratory direct-to-manufacturer prescription programs by state health agencies.

Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and state procurement offices administering multistate cooperative purchasing alliances (Minnesota Department of Administration through MMCAP). Recent opportunities span Florida, Texas, Minnesota, and Oregon. Representative solicitations include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB with quarterly deliveries to the Seminole County Community Health Building; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) requesting vendor capabilities for direct-to-manufacturer prescription programs; and the Minnesota Department of Administration's MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multistate contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and responses due through the ePro procurement system.